Latest developments in the imaging of fibrotic liver disease.
According to the World Health Organization, liver cirrhosis accounted for 1.8% of all deaths in Europe, causing about 170,000 deaths per year. Approximately 29 million persons in the EU suffer from chronic liver disease and this trend is on the rise. Liver disease is the EU's fifth most common cause of death accounting for at least one in six deaths. Early detection and monitoring of fibrosis has the potential to direct management of these chronic liver diseases and avert morbidity and mortality. Although the available techniques are in their infancy and the very early stages of fibrosis are difficult to detect, there have been significant advances in imaging over the last decade that has resulted in the use of these new imaging techniques being introduced into the patient pathway. This review explores the accuracies of these imaging techniques, their role in the management of patients, and the potential for the future.
Central Middlesex Hospital, Northwest London Hospitals NHS Trust, Acton, London, UK Imperial College, South Kensington, London, UK.
Minal J
MJ
Sangwaiya
Central Middlesex Hospital, Northwest London Hospitals NHS Trust, Acton, London, UK.
David I N
DI
Sherman
Addenbrooke's Hospital, Cambridge, UK.
David J
DJ
Lomas
Central Middlesex Hospital, Northwest London Hospitals NHS Trust, Acton, London, UK P.Shorvon@nhs.net.
Philip J
PJ
Shorvon
D015415:Biomarkers / Q000032:analysis; D003952:Diagnostic Imaging / Q000639:trends*; D005060:Europe; D005544:Forecasting; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis* / Q000378:metabolism*; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D057054:Molecular Imaging / Q000639:trends*
D015415:Biomarkers
Abdomen/GI; fibrosis; liver